Eton Pharmaceuticals (ETON) Work In Process (2024 - 2026)

Eton Pharmaceuticals has disclosed Work In Process across 3 years of filings, most recently posting $5.5 million for Q2 2026.

• In Q2 2026, Work In Process changed N/A year-over-year to $5.5 million; the TTM figure through Jun 2026 stood at $5.5 million (changed N/A YoY), while the FY2025 annual figure was $9.4 million, up 186.83% from the prior year.
• Work In Process came in at $5.5 million for Q2 2026 at Eton Pharmaceuticals, down from $9.4 million in the prior quarter.
• In the past five years, Work In Process ranged from a high of $9.4 million in Q4 2025 to a low of $3.3 million in Q4 2024.
• Average Work In Process over 3 years is $6.1 million, with a median of $5.5 million recorded in 2026.
• The largest YoY upside for Work In Process was 186.83% in 2025 against a maximum downside of 186.83% in 2025.
• Over 3 years, Work In Process stood at $3.3 million in 2024, then soared by 186.83% to $9.4 million in 2025, then tumbled by 41.73% to $5.5 million in 2026.
• Per Business Quant data, the three most recent Work In Process figures were $5.5 million in Q2 2026, $9.4 million in Q4 2025, and $3.3 million in Q4 2024.